[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0401790D0 - Tamoxifen response in pre- and postmenopausal breast cancer patients - Google Patents

Tamoxifen response in pre- and postmenopausal breast cancer patients

Info

Publication number
SE0401790D0
SE0401790D0 SE0401790A SE0401790A SE0401790D0 SE 0401790 D0 SE0401790 D0 SE 0401790D0 SE 0401790 A SE0401790 A SE 0401790A SE 0401790 A SE0401790 A SE 0401790A SE 0401790 D0 SE0401790 D0 SE 0401790D0
Authority
SE
Sweden
Prior art keywords
breast cancer
cancer patients
postmenopausal breast
tamoxifen response
tamoxifen
Prior art date
Application number
SE0401790A
Other languages
English (en)
Inventor
Goeran Landberg
Lisa Ryden
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Priority to SE0401790A priority Critical patent/SE0401790D0/sv
Publication of SE0401790D0 publication Critical patent/SE0401790D0/sv
Priority to PCT/SE2005/001116 priority patent/WO2006004545A1/en
Priority to EP05757471A priority patent/EP1773309A1/en
Priority to US11/620,275 priority patent/US20070213403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0401790A 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients SE0401790D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients
PCT/SE2005/001116 WO2006004545A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
EP05757471A EP1773309A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
US11/620,275 US20070213403A1 (en) 2004-07-07 2007-01-05 Tamoxifen response in pre-and postmenopausal breast cancer patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Publications (1)

Publication Number Publication Date
SE0401790D0 true SE0401790D0 (sv) 2004-07-07

Family

ID=32768801

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Country Status (4)

Country Link
US (1) US20070213403A1 (sv)
EP (1) EP1773309A1 (sv)
SE (1) SE0401790D0 (sv)
WO (1) WO2006004545A1 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
JP4728340B2 (ja) 2004-10-25 2011-07-20 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性を変調する化合物および変調方法
EP2834371B1 (en) * 2012-04-05 2019-01-09 The Regents of The University of California Gene expression panel for breast cancer prognosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539588A (en) * 1967-12-06 1970-11-10 American Home Prod Trans-1,4,4a,5,6,11b-hexahydro-11h-benzo(a) carbazol-5-one,thiosemicarbazones
US4769378A (en) * 1986-03-31 1988-09-06 Eli Lilly And Company Indenopyrimidine aromatase inhibitors
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
EP1137945A1 (en) * 1998-12-08 2001-10-04 Board of Regents, The University of Texas System Methods for detection of antiestrogen-resistant breast cancer
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
PL211834B1 (pl) * 2000-02-15 2012-06-29 Sugen Związki 2-indolinonowe, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
CA2424299A1 (en) * 2000-10-06 2002-04-18 Biomedicines, Inc. Combination therapy for the treatment of estrogen-sensitive disease
EP1458713B1 (en) * 2001-12-27 2005-08-24 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
AU2003209119A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1543009A4 (en) * 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
JP2006514991A (ja) * 2002-12-27 2006-05-18 シエーリング アクチエンゲゼルシャフト 新規医薬組合せ
US7226941B2 (en) * 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
WO2006004545A1 (en) 2006-01-12
US20070213403A1 (en) 2007-09-13
EP1773309A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
HRP20150437T1 (xx) Diarilhidantoinski spojevi kao antagonisti androgenog receptora za lijeäśenje raka
EP1864971A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
EP2035034A4 (en) GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
MXPA03011941A (es) Ligandos del receptor de 5-ht y sus usos.
TNSN07005A1 (fr) Analogues tetrapeptidiques
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
TN2009000371A1 (fr) Composition pharmaceutique
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP1848275A4 (en) LIGANDS OF THE OPIOID RECEPTOR KAPPA
DE602007006280D1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
DK1865931T3 (da) Transdermal plaster
EP2018873A4 (en) Prophylactic/therapeutic agent for cancer
LT2012006A (lt) 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui
EA200970816A1 (ru) Новая лекарственная форма